Abbott is rolling out the latest iteration of its Navitor transcatheter aortic valve implantation (TAVI) system, the Navitor Vision, across UK and Ireland.
The Navitor Vision valve is a minimally invasive device that allows doctors to treat patients with severe aortic stenosis who are at high or extreme surgical risk for surgery. The latest iteration of the device is designed to help doctors implant more precisely and at the intended depth, featuring radiopaque markers that are designed to be more visible during the implant procedure.
Navitor Vision is offered in a range of sizes to treat native annulus diameters from 19–30 mm, with a sealing cuff that actively synchronises to the patient’s cardiac cycle and seals against even the most challenging anatomies. This makes it the biggest TAVI valve size delivered through the smallest delivery system available on the NHS, Abbott says in a press release.
Matt Scrivener, Abbott’s country manager for structural heart, UK and Ireland, said: “For patients with severe aortic stenosis who are at high or extreme surgical risk, due to the potential complications stemming from age, frailty, or comorbidities, it’s great to now be able to offer their doctors across the UK and Ireland an option which offers stable delivery, remarkable performance, and is built for the future.
“The Navitor Vision valve can help to reduce symptoms and improve the lives of patients with aortic stenosis, through higher levels of precision and visibility during deployment. Aortic stenosis is such a debilitating condition for so many people in the UK and our goal is to continue to develop technologies like this that enable people to live the best lives they can.”
